26829-47-0

Usage

Uses

Used in Pharmaceutical Industry:
7-Methylisoquinolin-1(2H)-one is used as a key intermediate in the synthesis of various drugs and pharmaceutical compounds. Its unique chemical structure and properties make it a valuable building block for the development of novel bioactive molecules with potential therapeutic applications.
Used in Antiviral Applications:
7-Methylisoquinolin-1(2H)-one has been studied for its potential antiviral properties. Its ability to inhibit viral replication and reduce the severity of viral infections makes it a promising candidate for the development of antiviral drugs.
Used in Anticancer Applications:
7-Methylisoquinolin-1(2H)-one has also been investigated for its potential anticancer properties. Its ability to target and inhibit the growth of cancer cells, as well as its potential to enhance the efficacy of existing chemotherapeutic agents, makes it a promising candidate for cancer research and drug development.
Used in Medicinal Chemistry and Drug Discovery:
Due to its unique chemical structure and properties, 7-methylisoquinolin-1(2H)-one is extensively used in medicinal chemistry and drug discovery. It serves as a versatile molecule for the design and synthesis of novel bioactive compounds with potential applications in various therapeutic areas.

InChI:InChI=1/C10H9NO/c1-7-2-3-8-4-5-11-10(12)9(8)6-7/h2-6H,1H3,(H,11,12)

Upstream product

• 99-04-7 m-Toluic acid 
• 24186-45-6 1-(2-isocyanato-vinyl)-4-methyl-benzene 
• 13162-05-5 n-vinylformamide 
• 24186-38-7 C₁₀H₉N₃O 
• 1711-06-4 3-Methylbenzoyl chloride 
• 133933-18-3 N-(3-toluoyl)aminoacetaldehyde dimethyl acetal 
• 330962-44-2 (E)-1-azido-3-(4-methylphenyl)prop-2-en-1-one 

Downstream Products

• 24188-80-5 1-chloro-7-methylisoquinoline 
• 444898-40-2 C₃₆H₂₉NO₈ 
• 1010688-97-7 C₃₁H₂₉NO₆ 
• 209285-92-7 7-bromomethyl-1-chloro-isoquinoline 
• 133933-21-8 (S)-2-{4-[(1-Oxo-1,2-dihydro-isoquinolin-7-ylmethyl)-prop-2-ynyl-amino]-benzoylamino}-pentanedioic acid diethyl ester 
• 133933-13-8 2-desamino-N¹⁰-propargyl-1,5,8-trideazafolic acid 

Relevant academic research and scientific papers

Aromatic compounds and preparation method and application thereof

The invention discloses aromatic compounds and a preparation method and application thereof. The preparation method of the aromatic compounds includes the step of performing a cyclization reaction between an amide compound and a benzoic acid compound in the presence of a rhodium catalyst, a metal oxidant and base, wherein the aromatic compounds are isoquinolinone compounds or isocoumarin derivatives, and the amide compound is N-vinylformamide or N-vinylacetamide. Through the synergistic effect of the rhodium catalyst, the metal oxidant and the base, the isoquinolinone compounds or isocoumarinderivatives are obtained through the one-step reaction between the benzoic acid compound and the amide compound. The reaction has simple operation, the raw materials are cheap and easily available, reaction substrates can be selected flexibly according to the required isoquinolinone compounds and the isocoumarin derivatives, and the synthesized isoquinolinone compounds and the isocoumarin derivatives can be used as a backbone structure in multiple biologically active molecules and natural products, and have high practicality.

Divergent Synthesis of Isoquinolone and Isocoumarin Derivatives by the Annulation of Benzoic Acid with N-Vinyl Amide

A simple and efficient method for the synthesis of isoquinolone and isocoumarin derivatives is reported. The method for the first time provides a one-step divergent synthesis of important isoquinolone and isocoumarin skeletons from benzoic acid by switching the coupling partners. In addition, a reliable mechanism has been proposed on the basis of experimental investigations, including kinetic isotope effect experiments, 13C labeling experiments, time-tracking experiments, and competitive experiments, as well as DFT calculation studies.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

PYRIDINES AND PYRIDINE N-OXIDES AS MODULATORS OF THROMBIN

The present invention describes compounds of Formula I: wherein W, X, Y, Z, and Q are defined herein, or a pharmaceutically acceptable salt thereof, for the prophylaxis, or treatment of diseases and conditions related to thrombin activity in a mammal.

Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin

The compounds of the present invention are represented by the chemical structure found in Formula (I): wherein: the carbon atom designated * is in the R or S configuration; and X is a fused bicyclic carbocycle or heterocycle selected from the group consisting of benzofuranyl, benzo[b]thiophenyl, benzoisothiazolyl, benzoisoxazolyl, indazolyl, indolyl, isoindolyl, indolizinyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl, benzotriazolyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, thieno[2,3-b]pyridinyl, thieno[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, indenyl, indanyl, dihydrobenzocycloheptenyl, tetrahydrobenzocycloheptenyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, indolinyl, naphthyl, tetrahydronaphthyl, quinolinyl, isoquinolinyl, 4H-quinolizinyl, 9aH-quinolizinyl, quinazolinyl, cinnolinyl, phthalazinyl, quinoxalinyl, benzo[1,2,3]triazinyl, benzo[1,2,4]triazinyl, 2H-chromenyl, 4H-chromenyl, and a fused bicyclic carbocycle or fused bicyclic heterocycle optionally substituted with substituents (1 to 4 in number) as defined in R14; with R1, R2, R3, R4, R5, R6, R7, R8, and R14 defined herein.

HEPATITIS C VIRUS INHIBITORS

Hepatitis C virus inhibitors are disclosed having the general formula:(I) wherein R1, R2, R3, R', B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds toinhibit HCV are also disclosed.

Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds

The compounds of formula I herein exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, for treating a patient suffering from, or subject to, a physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

Aminoisoquinolines: Design and synthesis of an orally active benzamidine isostere for the inhibition of factor Xa.

The design, synthesis and SAR of sulfonamidopyrrolidinone fXa inhibitors incorporating a new benzamidine isostere, namely aminoisoquinolines, is described. These inhibitors have higher Caco-2 cell permeability than comparable benzamidines and attain higher levels of exposure upon oral dosing. The most potent member 14b (fXa Ki=6 nM) is selective against other serine proteasesof interest (>600 fold).

Folate analogues. 35. synthesis and biological evaluation of 1-deaza, 3-deaza, and bridge-elongated analogues of n10-propargyl-5, 8-dideazafolic acid1

Structural modifications at the pyrimidine ring and at the C9,N10-bridge region of the thymidylate synthase (TS) inhibitors N10-propargyl-5,8-dideazafolate (1; PDDF; CB 3717), 2-desamino-N10-propargyl-5,8-dideaz